ELTP Stock Updates 08/25/2014 07:29:38 $ELTP
Sounds good. I think there will be a lot more people at the R & R Conference this year. I think last year Couch said there was around 30. I expect 60 or more this time around. Then again, not sure how big the room is and how many people it can hold.
Nasrat has a veteran's cleverness and not a newbie's impetuousness. He know's when to play the cards and not fold. He is going for the big ante where winner $ELTP takes all. He has been at the helm of the major pharmas with vast hands on experience and $ELTP shareholders need to trust his judgement.
No way he is screwing up. A year from now in Aug 2015 will be night and day difference for $ELTP PPS.
$ELTP reaches the Global Pharmas at Rodmand and Renshaw Sept 8 to 10 2014 NY and $Elite makes its latest and newest public presentation since a year ago.
http://www.rodm.com/
Quote:
Presenting Companies
Elite Pharmaceuticals, Inc. (OTCQB: ELTP) (Website)
AS for Generics launching if you are referring to Isradipine
Doug Plassche has done a marvellous job in securing the API for Isradipine. It has been a very difficult process and the supplier of Isradipine wanted to be assured that $ELTP would take the entire batch for Isradipine starting API. The only other seller of Isradipine is Actavis/Watson. Doug Plassche is a leading expert on Isradipine from his employment at Actavis. $ELTP is very blessed to have such a talented VP of Operations Doug Plassche.
Quote:
Doug Plassche
Okay. Actually it’s the [alarm] (ph). So let me walk you through it. I do believe I’ve covered this before. I apologize if you weren’t on the call or I did not emphasize them up. We made Isradipine at our facility in here at Northvale. We put it on stability. We created the CBE-30 and we filed it to the FDA. We had a strict feedback from center that they want us to – they said the CBE-30 is still open. We would like you to validate the process before you launch it. And they literally said to us, you can validate the process and launch and then notify us. So from their standpoint we can move forward.
The issues we encountered is the same issues that a lot public companies encounter. First, the API manufacturer was the only AP. We had single source API manufacturer in our application. So, in order for them to sell us product for us to go ahead and validate they requested first that we pay the PDUFA fee on their behalf. They were not using their DMF. So they wanted us to pay that. We paid it. It was like $36,000 or so.
Then they demanded that we buy all of the raw materials that go into making Isradipine. So we have to fork another chat for $125,000 and then we had to buy the entire lot from them, which we did and the entire lot was API which is lot of API and a lot of negotiations took place between Doug Plassche and these people in order to finally to get us the API. Now that we have the API Doug needs a prioritize it and I anticipate that we will go ahead and finish that edition and launch in Q4 of this year.
ELTP Stock Message Board http://investorshangout.com/Elite-Pharmaceuti...LTP-61177/
Great. That will make me more money. Nasrat knows best and we just have to let him do his job. Everyone just relax and get rich.
That's what the CEO said and I believe him. Anything else is just noise without links.
total nonsense
Two BIG Pharma's went out of their way to contact Elite.
The negotiations have been on going.
ELTP's buyout price rising with each passing day.
Listen to last few CC's
Unidentified Analyst
Given that Elite’s generic NDA ART line takes less time and money to bring to market then Elite’s once daily ELI-216 product can you speak to what the current plans are for this product say for instance to partner a combo ELI-201 and ELI-216 together and how quickly you are planning to move forward with this product as there is no once-daily abuse resistant product on the market to date
Doug Plassche - Executive Vice President-Operations
Obviously that’s a very interesting question and I think about that a lot, to take products like this to market by ourselves would require a lot of money. Mr. Ward here thinks day and night on how he can get me another $50 million, but definitely all options are on the table and I have no issue and I have talked to other companies about partnering with us in order to cover the clinical trial cost
But But But But, Big Pharma loves Elite. Well maybe likes Elite? Oh No, Big Pharma could care less about Elite! I suspected it was all hype.
CEO has enough funds NOW for 4-5 ADT opiods. These drugs will be generating BILLIONS. No need for additional shares.
ELI-201 will launch my retirement
Its is clear that investors, long and otherwise, agree with the potential buyer that Elite is way over valued. Both are reflected one by no buyer and the other by the buy orders usually all way below the BID.
AMEN to all of that. CEO will attempt to go it alone if he has to issue 5B more shares. He apparently doesn't like generics but he liked them enough to dump 12 of them on to Elite for a very generous price, thanks to JT.
Why is Nasrat trying to be so cocky??? Just sign with a big pharma and be done with it.
He's going to end up screwing up the launch of ELI-200 or something else bad is going to happen.
We are too small to be thinking we can just do it alone.
WE CAN'T EVEN LAUNCH FDA APPROVED GENERICS ON TIME!!!!!!!!!!!!!!!!!!!!!
Nobody cares about where this stock goes tomorrow, next week, or next month.
Shareholders are waiting for the buyout so they get the MAX RETURN for their investment.
Call me when we get bought out.
Couldn't care less what happens until then.
As long as Elite and the FDA gets along well !!!! As far as a buyout, there of course must be an agreed price and Nasrat may feel Elite is much more valuable than a buyer feels it is ... Either way as long as Elite gets FDA approval we are in the $$$$$
IB_
Last week of August!! Let the good times roll! This week will be interesting with different parties jockeying for position before Autumn. Locked and loaded and ready for football and ELTP INCREASES!!!!!!
The longer Nasrat goes it alone the greater the value of ELITE becomes, and the lower the risk for the acquiring company.
Are you coinciding this with your appearance at the Rodman Conference to have substantial presentation there with new products from Elite.
Nasrat Hakim - President and Chief Executive Officer
That really sound like it is, but it’s not. The Rodman Conference is early in the month, its eighth through tenth I believe. And the results that we are getting will be towards the end of the month and the final the reports will be in October
Starting to look like Elite may not have that "ONE Big Pharma" partner merging or buying out Elite as Nasrat now says we are going it alone !!!!
IB_
Only ONE Big Pharma will end up liking ELTP.
The ONE who ends up partnering, merging or buying out Elite.
The rest don't need the competition ...
ELTP
living for ELI-201
Sounds good. I think there will be a lot more people at the R & R Conference this year. I think last year Couch said there was around 30. I expect 60 or more this time around. Then again, not sure how big the room is and how many people it can hold.
Nasrat has a veteran's cleverness and not a newbie's impetuousness. He know's when to play the cards and not fold. He is going for the big ante where winner $ELTP takes all. He has been at the helm of the major pharmas with vast hands on experience and $ELTP shareholders need to trust his judgement.
No way he is screwing up. A year from now in Aug 2015 will be night and day difference for $ELTP PPS.
$ELTP reaches the Global Pharmas at Rodmand and Renshaw Sept 8 to 10 2014 NY and $Elite makes its latest and newest public presentation since a year ago.
http://www.rodm.com/
Quote:
Presenting Companies
Elite Pharmaceuticals, Inc. (OTCQB: ELTP) (Website)
AS for Generics launching if you are referring to Isradipine
Doug Plassche has done a marvellous job in securing the API for Isradipine. It has been a very difficult process and the supplier of Isradipine wanted to be assured that $ELTP would take the entire batch for Isradipine starting API. The only other seller of Isradipine is Actavis/Watson. Doug Plassche is a leading expert on Isradipine from his employment at Actavis. $ELTP is very blessed to have such a talented VP of Operations Doug Plassche.
Quote:
Doug Plassche
Okay. Actually it’s the [alarm] (ph). So let me walk you through it. I do believe I’ve covered this before. I apologize if you weren’t on the call or I did not emphasize them up. We made Isradipine at our facility in here at Northvale. We put it on stability. We created the CBE-30 and we filed it to the FDA. We had a strict feedback from center that they want us to – they said the CBE-30 is still open. We would like you to validate the process before you launch it. And they literally said to us, you can validate the process and launch and then notify us. So from their standpoint we can move forward.
The issues we encountered is the same issues that a lot public companies encounter. First, the API manufacturer was the only AP. We had single source API manufacturer in our application. So, in order for them to sell us product for us to go ahead and validate they requested first that we pay the PDUFA fee on their behalf. They were not using their DMF. So they wanted us to pay that. We paid it. It was like $36,000 or so.
Then they demanded that we buy all of the raw materials that go into making Isradipine. So we have to fork another chat for $125,000 and then we had to buy the entire lot from them, which we did and the entire lot was API which is lot of API and a lot of negotiations took place between Doug Plassche and these people in order to finally to get us the API. Now that we have the API Doug needs a prioritize it and I anticipate that we will go ahead and finish that edition and launch in Q4 of this year.
ELTP Stock Message Board http://investorshangout.com/Elite-Pharmaceuti...LTP-61177/
Great. That will make me more money. Nasrat knows best and we just have to let him do his job. Everyone just relax and get rich.
That's what the CEO said and I believe him. Anything else is just noise without links.
total nonsense
Two BIG Pharma's went out of their way to contact Elite.
The negotiations have been on going.
ELTP's buyout price rising with each passing day.
Listen to last few CC's
Unidentified Analyst
Given that Elite’s generic NDA ART line takes less time and money to bring to market then Elite’s once daily ELI-216 product can you speak to what the current plans are for this product say for instance to partner a combo ELI-201 and ELI-216 together and how quickly you are planning to move forward with this product as there is no once-daily abuse resistant product on the market to date
Doug Plassche - Executive Vice President-Operations
Obviously that’s a very interesting question and I think about that a lot, to take products like this to market by ourselves would require a lot of money. Mr. Ward here thinks day and night on how he can get me another $50 million, but definitely all options are on the table and I have no issue and I have talked to other companies about partnering with us in order to cover the clinical trial cost
But But But But, Big Pharma loves Elite. Well maybe likes Elite? Oh No, Big Pharma could care less about Elite! I suspected it was all hype.
CEO has enough funds NOW for 4-5 ADT opiods. These drugs will be generating BILLIONS. No need for additional shares.
ELI-201 will launch my retirement
Its is clear that investors, long and otherwise, agree with the potential buyer that Elite is way over valued. Both are reflected one by no buyer and the other by the buy orders usually all way below the BID.
AMEN to all of that. CEO will attempt to go it alone if he has to issue 5B more shares. He apparently doesn't like generics but he liked them enough to dump 12 of them on to Elite for a very generous price, thanks to JT.
Why is Nasrat trying to be so cocky??? Just sign with a big pharma and be done with it.
He's going to end up screwing up the launch of ELI-200 or something else bad is going to happen.
We are too small to be thinking we can just do it alone.
WE CAN'T EVEN LAUNCH FDA APPROVED GENERICS ON TIME!!!!!!!!!!!!!!!!!!!!!
Nobody cares about where this stock goes tomorrow, next week, or next month.
Shareholders are waiting for the buyout so they get the MAX RETURN for their investment.
Call me when we get bought out.
Couldn't care less what happens until then.
As long as Elite and the FDA gets along well !!!! As far as a buyout, there of course must be an agreed price and Nasrat may feel Elite is much more valuable than a buyer feels it is ... Either way as long as Elite gets FDA approval we are in the $$$$$
IB_
Last week of August!! Let the good times roll! This week will be interesting with different parties jockeying for position before Autumn. Locked and loaded and ready for football and ELTP INCREASES!!!!!!
The longer Nasrat goes it alone the greater the value of ELITE becomes, and the lower the risk for the acquiring company.
Are you coinciding this with your appearance at the Rodman Conference to have substantial presentation there with new products from Elite.
Nasrat Hakim - President and Chief Executive Officer
That really sound like it is, but it’s not. The Rodman Conference is early in the month, its eighth through tenth I believe. And the results that we are getting will be towards the end of the month and the final the reports will be in October
Starting to look like Elite may not have that "ONE Big Pharma" partner merging or buying out Elite as Nasrat now says we are going it alone !!!!
IB_
Only ONE Big Pharma will end up liking ELTP.
The ONE who ends up partnering, merging or buying out Elite.
The rest don't need the competition ...
ELTP
living for ELI-201
